Emergent BioSolutions, Inc. (EBS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$5.68-5.33%
Close 2026-09-09 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Broken: Primary pillar broken — Achieve full year 2026 revenue between $720M and $760M: FY26 rev guide $645M-$675M vs $720M-$760M target.
Emergent BioSolutions aims for $720M to $760M revenue in 2026. Profit margins target 45% to 47%. Q2 revenue is expected to rise to $170M-$185M. Government contracts support steady funding.
Revenue and margin targets are challenging amid volatile management. Past earnings missed guidance. Government funding could slow or end. The stock trades cheap for a reason.
The market expects about 20% revenue growth and values EBS cheaply with a PE of 8.3 versus peers at 25. Our fair value is near $21.57, reflecting cautious optimism on meeting guidance.
Breaks if: Adjusted gross margin falls below 45% in FY26
Breaks if: Loss or non-renewal of key government contracts
Q2 revenue falls below $170M
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on restructuring and revenue growth. The current thesis is intact but faces volatility due to management changes and market conditions.
The valuation suggests that the market views EBS as cheap compared to its peers, but there is a notable expectations gap. The current pricing reflects concerns about execution quality and the company's fragile earnings.
Management is focused on restructuring to improve costs while maintaining revenue growth from government contracts. Recent results show a significant revenue increase, but the overall earnings quality remains fragile.
The long-term thesis hinges on management's ability to execute its restructuring plan and the broader healthcare sector's performance. Key factors include potential earnings guidance changes and the impact of economic conditions on cyclical names like EBS.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company repurchased $75 million in senior notes. This improves financial flexibility and reduces interest expense. However, there are challenges to revenue guidance for 2026. Analysts cut revenue outlook due to increased competition. This could hinder revenue growth through government contracts and partnerships.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Full year revenue falls below $720M in FY26
Continue to achieve total revenues in the range of $720 million to $760 million for the full year 2026.
Over the next 1 to 3 years, EBS will need to demonstrate consistent execution and leverage sector momentum to stabilize its position. Not investment advice.